ASCO 2024 | Mosunetuzumab in the treatment of HCL: a case study
Tamar Tadmor
• 31 May 2024
Tamar Tadmor, MD, Bnai Zion Medical Center, Haifa, Israel, discusses a case study of a patient with relapsed/refractory (R/R) hairy cell leukemia (HCL) who was treated with mosunetuzumab. After exhausting all available HCL treatments, the patient achieved a sustained response for over a year with mosunetuzumab. This case serves as proof of concept for using mosunetuzumab in HCL treatment. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
